<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190922044839N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-22</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Immediate effects of transcranial direct current stimulation on upper extremity performance under dual-task condition in stroke</public_title>
      <acronym></acronym>
      <scientific_title>Immediate effects of transcranial direct current stimulation of motor and cognitive cortex on upper extremity performance under dual-task condition in people with subacute stroke</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53263</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: A simple individual randomization via a statistical software will be performed.
We will use the Win Pepi for making randomization order.
Allocation concealment will be performed by the secretary of the assessment center, Blinding description: All participants in this study will be blind to their allocation to study groups (motor cortex stimulation, cognitive cortex stimulation and placebo). The outcome assessor, before and after intervention, will be blind to the allocation as well. However, the physiotherapist, study designer, statistical analyst and the committee of safety and data supervision will not be blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Stroke.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Motor cortex stimulation: The participants in the motor cortex intervention group will receive one bilateral tDCS treatment session with the intensity of 1 milliamperes for 20 minutes in the primary  motor area (M1). In this group, the anode electrode will be placed on the M1 area of the involved hemisphere and the cathode electrode will be placed on the M1 area of the intact hemisphere. It should be noted that the tDCS device is a nerve modulator device that includes a battery and at least two electrodes. The battery has a resistance of 9 volts. Each device must have only one anode source and one cathode evolution, one of which must be located on the head. The changes are covered with a sponge soaked in saline or other semiconductor material. The size of the changes varies between 16, 25, 35, 36 square centimeters. 2mA is the highest current strongest tested by experience, but powerful devices have increased dramatically (3-4mA). The most used current density is in the range of 0.028-0.06 current per square centimeter. Intervention 2: Intervention group 2: Cognitive cortex stimulation: The participants in the motor cortex intervention group will receive one bilateral tDCS treatment session with the intensity of 1 milliamperes for 20 minutes in the dorsolateral prefrontal cortex (DLPFC). In this group, the anode electrode will be placed on the DLPFC area of the involved hemisphere and the cathode electrode will be placed on the DLPFC area of the intact hemisphere. It should be noted that the tDCS device is a nerve modulator device that includes a battery and at least two electrodes. The battery has a resistance of 9 volts. Each device must have only one anode source and one cathode evolution, one of which must be located on the head. The changes are covered with a sponge soaked in saline or other semiconductor material. The size of the changes varies between 16, 25, 35, 36 square centimeters. 2mA is the highest current strongest tested by experience, but powerful devices have increased dramatically (3-4mA). The most used current density is in the range of 0.028-0.06 current per square centimeter. Intervention 3: Control group: Placebo: Cognitive cortex stimulation: The participants in the control group will receive a tDCS  session with an elctrode placement similar to either of motor intervention group or cognitive intervention group, however they will receive tDCS only for the first 30 seconds and the rest of the time will be currentless.  It should be noted that the tDCS device is a nerve modulator device that includes a battery and at least two electrodes. The battery has a resistance of 9 volts. Each device must have only one anode source and one cathode evolution, one of which must be located on the head. The changes are covered with a sponge soaked in saline or other semiconductor material. The size of the changes varies between 16, 25, 35, 36 square centimeters. 2mA is the highest current strongest tested by experience, but powerful devices have increased dramatically (3-4mA). The most used current density is in the range of 0.028-0.06 current per square centimeter.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I have to provide all the data to the research sponsor.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tabassom Ghanavati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>29 Bahman Blvd, Tabriz University, Faculty of Rehabilitation Sciences</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3337 2072</telephone>
        <email>ghanavatit@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tabassom Ghanavati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>29th Bahman BLVD, Tabriz University, Rehabilitation Faculty</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3337 2072</telephone>
        <email>ghanavatit@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
Physical ability to complete the motor activities required in examine by the examiner (ability to tap with the finger and perform a Purdepeg board test)
Awareness and ability to communicate with the examiner and therapist
Level of cognition enough to understand the test (score 22 or higher on the short test of mental state by the examiner)
Score less than 18 upper limbs in the Fugel_Meyer test
The first unilateral stroke that is at least 4 weeks old
Confirmation of a stroke by one of the methods of brain imaging by a doctor</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Contraindications to tDCS include: having a pacemaker, metal implants, a history of seizures, a skin rash, allergies or sores where the electrodes are placed, and cranial skin sensitivity.
Severe upper limb pain (visual pain scale greater than 5)
speech problem
Existence of orthopedic or neurological disorder in the upper limb involved
Upper extremity spasticity of less than 2 or more than 15 on the modified Ashworth scale</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I64</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Stroke, not specified as haemorrhage or infarction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Motor cortex stimulation: The participants in the motor cortex intervention group will receive one bilateral tDCS treatment session with the intensity of 1 milliamperes for 20 minutes in the primary  motor area (M1). In this group, the anode electrode will be placed on the M1 area of the involved hemisphere and the cathode electrode will be placed on the M1 area of the intact hemisphere. It should be noted that the tDCS device is a nerve modulator device that includes a battery and at least two electrodes. The battery has a resistance of 9 volts. Each device must have only one anode source and one cathode evolution, one of which must be located on the head. The changes are covered with a sponge soaked in saline or other semiconductor material. The size of the changes varies between 16, 25, 35, 36 square centimeters. 2mA is the highest current strongest tested by experience, but powerful devices have increased dramatically (3-4mA). The most used current density is in the range of 0.028-0.06 current per square centimeter.</i_keyword>
      <i_keyword>Intervention group 2: Cognitive cortex stimulation: The participants in the motor cortex intervention group will receive one bilateral tDCS treatment session with the intensity of 1 milliamperes for 20 minutes in the dorsolateral prefrontal cortex (DLPFC). In this group, the anode electrode will be placed on the DLPFC area of the involved hemisphere and the cathode electrode will be placed on the DLPFC area of the intact hemisphere. It should be noted that the tDCS device is a nerve modulator device that includes a battery and at least two electrodes. The battery has a resistance of 9 volts. Each device must have only one anode source and one cathode evolution, one of which must be located on the head. The changes are covered with a sponge soaked in saline or other semiconductor material. The size of the changes varies between 16, 25, 35, 36 square centimeters. 2mA is the highest current strongest tested by experience, but powerful devices have increased dramatically (3-4mA). The most used current density is in the range of 0.028-0.06 current per square centimeter.</i_keyword>
      <i_keyword>Control group: Placebo: Cognitive cortex stimulation: The participants in the control group will receive a tDCS  session with an elctrode placement similar to either of motor intervention group or cognitive intervention group, however they will receive tDCS only for the first 30 seconds and the rest of the time will be currentless.  It should be noted that the tDCS device is a nerve modulator device that includes a battery and at least two electrodes. The battery has a resistance of 9 volts. Each device must have only one anode source and one cathode evolution, one of which must be located on the head. The changes are covered with a sponge soaked in saline or other semiconductor material. The size of the changes varies between 16, 25, 35, 36 square centimeters. 2mA is the highest current strongest tested by experience, but powerful devices have increased dramatically (3-4mA). The most used current density is in the range of 0.028-0.06 current per square centimeter.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cognitive test score of Auditory Stroop test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Software.</prim_outcome>
      <prim_outcome>Motion test score of unilateral simple Fugl_meyer test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Software.</prim_outcome>
      <prim_outcome>Motion test score of Purdue Pegboard board test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Examiner.</prim_outcome>
      <prim_outcome>Cost of cognitive dual task conditions for combining Purdue Pegboard board test and Auditory Stroop test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Voice recording and calculation.</prim_outcome>
      <prim_outcome>Cost of cognitive dual-task conditions for combining unilateral simple Fugl_meyer test and Auditory Stroop test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Voice recording and calculation.</prim_outcome>
      <prim_outcome>Cost of dual task conditions for combining Purdue Pegboard board test and Auditory Stroop test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Calculation.</prim_outcome>
      <prim_outcome>Cost of dual task conditions to combine unilateral simple Fugl_meyer test and Auditory Stroop test. Timepoint: Before intervention and immediately after intervention. Method of measurement: Voice recording and calculation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-01</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>29th Bahman Blvd, Tabriz University, Faculty of Rehabilitation Sciences Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
